EUVIMEDEUVIMED entdecken
Crossref

Effect of early administration of sacubitril/valsartan in ST-elevation myocardial infarction patients undergoing PCI: Impact on infarct size and ventricular remodeling

Lei Sun

Pakistan Journal of Pharmaceutical Sciences · 18.11.2026

DOI: 10.36721/pjps/2026.40.16612.1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pakistan Journal of Pharmaceutical Sciences, online erschienen am 18.11.2026. Verfasst von Lei Sun. Die Arbeit nennt 26 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Adverse left ventricular remodeling remains a major determinant of heart failure and mortality in patients with ST-elevation myocardial infarction (STEMI) despite successful primary percutaneous coronary intervention (PCI). Sacubitril/valsartan has shown beneficial effects on ventricular remodeling in heart failure populations; however, evidence regarding its early initiation following STEMI remains limited.

Objectives

To evaluate the association of early sacubitril/valsartan initiation with infarct-size markers and ventricular remodeling outcomes in STEMI patients undergoing primary PCI.

Methods

This retrospective observational cohort study included 150 consecutive STEMI patients treated with primary PCI at Tianjin Hospital, China, between January 2020 and December 2024. Patients were categorized into an angiotensin receptor–neprilysin inhibitor (ARNI) group receiving sacubitril/valsartan within 7 days of STEMI or a control group receiving standard ACEI/ARB therapy. Ventricular remodeling was assessed using serial echocardiographic measurements including left ventricular ejection fraction (LVEF), left ventricular end-diastolic volume (LVEDV) and left ventricular end-systolic volume (LVESV). Clinical outcomes were evaluated with a minimum follow-up of 6 months.

Results

Baseline demographic and procedural characteristics were comparable between groups. Patients receiving early sacubitril/valsartan demonstrated lower peak cardiac biomarker levels and greater improvement in follow-up LVEF compared with the control group. Adverse ventricular remodeling occurred less frequently in the ARNI group. Heart failure–related hospitalizations were lower among patients receiving sacubitril/valsartan, whereas all-cause mortality and adverse event rates were comparable between groups. Multivariable analysis demonstrated that early sacubitril/valsartan initiation was associated with favorable ventricular remodeling.

Conclusion

Early sacubitril/valsartan initiation after STEMI treated with primary PCI was associated with improved ventricular remodeling and better recovery of left ventricular systolic function in this retrospective cohort. These findings should be considered hypothesis-generating and require confirmation in larger prospective randomized studies.

Zitieren

APA

Sun, L. (2026). Effect of early administration of sacubitril/valsartan in ST-elevation myocardial infarction patients undergoing PCI: Impact on infarct size and ventricular remodeling. Pakistan Journal of Pharmaceutical Sciences. https://doi.org/10.36721/pjps/2026.40.16612.1

Vancouver

Sun L. Effect of early administration of sacubitril/valsartan in ST-elevation myocardial infarction patients undergoing PCI: Impact on infarct size and ventricular remodeling. Pakistan Journal of Pharmaceutical Sciences. 2026. doi:10.36721/pjps/2026.40.16612.1

BibTeX
@article{Sun2026,
  author = {Sun, Lei},
  title = {Effect of early administration of sacubitril/valsartan in ST-elevation myocardial infarction patients undergoing PCI: Impact on infarct size and ventricular remodeling},
  journal = {Pakistan Journal of Pharmaceutical Sciences},
  year = {2026},
  doi = {10.36721/pjps/2026.40.16612.1}
}
Kostenlos starten →